Page 4 - Lupin

Lupin, Hindalco: 3 stocks to buy today by Ajit Mishra of Religare Broking

Nifty 50 Today: The Nifty index may continue to consolidate after its recent surge, but the broader trend remains positive

Lupin surges 8% in 2 days on USFDA nod for generic HIC drug

The drugs include Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets and the company is the exclusive first-to-file for this products

Lupin receives USFDA approval to market its generic HIV medications

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets, the Mumbai-base drug maker said in a statement. The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension, it added. This product would be manufactured at the drug firm's Nagpur facility and will be supplied to low-and middle-income countries, it said. The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg. "The tentative approval from the USFDA for our Abacavir, Dolutegravir and

Lupin receives US FDA tentative approval for Ivacaftor Oral Granules

These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral Granules

Lupin shares rise but pares gains soon; here's what moved stock in trade

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024

Lupin gets clearance from USFDA for its Pithampur manufacturing facility

Lupin, headquartered in Mumbai, India, is a global pharmaceutical player with products distributed in over 100 markets

Lupin, IREDA, AWL: These 4 buzzing stocks can rally up to 28%; hint charts

IREDA stock is seen attempting a breakout on the daily scale, while SJVN is testing support at the key monthly moving average, which the stock has held since August 2020; shows the technical charts.

Lupin up 2%, hits new high on buying Eli Lilly's diabetes drug Huminsulin

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per cent during the period

Stocks to Watch, Dec 31, 2024: RIL, Lupin, ITC, Adani Enterprises, SpiceJet

Stocks to Watch on Dec 31, 2024: From ITC to Adani Enterprises, here are few stocks that will remain in focus today

Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

Chandan Taparia of MOFSL recommends buying these stocks on Dec 26

Lupin stock has broken out of a triple bottom pattern on the daily chart. It has also crossed above its key moving average suggesting bullish sentiment

Stocks to Watch, Dec 16: RIL, Dixon Tech, Lupin, Zinka Logistics, Sky Gold

Stocks to watch on Monday, December 16, 2024: Dixon Technologies signs a binding term sheet with Vivo India for a proposed joint venture

Nandish Shah of HDFC Securities suggests Bull Spread strategy on Lupin

Long build up is seen in the Lupin Futures, where we have seen 2 per cent rise in the open interest with price rising by 1 per cent

Lupin shares gain 3% after USFDA approves type-2 diabetes drug; details

Lupin share price gained after the company announced that it has received tentative approval from the United States Food and Drug Administration (US FDA)

Stocks to Watch, Nov 26: HUL, SBI, Coal India, IndiGo, Adani Group shares

Stocks to Watch, Nov 26: Here is a list of stocks that will be in focus for today's session

Lupin recalls over 600,000 bottles of hypertension drug in US: USFDA

Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP), according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA), stated that Dr Reddy's Laboratoties is also recalling a product in the US due to a manufacturing issue. Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of Mumbai-based Lupin, is recalling 6,16,506 bottles of Ramipril capsules in strengths of 2.5 mg, 5 mg and 10 mg, the US health regulator said. The affected lot is manufactured at Lupin's Goa-based manufacturing facility, it stated. The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets, it said. The US health regulator noted that the company is undertaking Class II voluntary recall due to "CGMP Deviations: Active pharmaceutical ingredient was sourced from an

Stocks to Watch, Nov 8: Lupin, Cochin Shipyard, Astral, Emami, RVNL, NHPC

Stocks to watch, November 8, 2024: Cochin Shipyard reported a Q2FY25 net profit of Rs 193 crore, which is slightly lower than Rs 200 crore in the same period last year

Lupin Q2FY25 results: Net profit jumps 74% to Rs 853 cr on strong demand

Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to Rs 853 crore (about $101 million) for the quarter ended Sept. 30

Q2 results today: M&M, Lupin, NHPC, and RVNL among 166 to post earnings

Q2 results today, November 7: Trent, Abbott India, Aditya Birla Fashion and Retail, and more will release their Q2FY25 performance report

Lupin Q2 Preview: Profits may rise 42% YoY led by steady India, US sales

Brokerages expect Lupin to report a strong quarter on a year-on-year basis, while a quieter one sequentially